000			01876 a2200445 4500
005			20250515122739.0
264		0	_c20080922
008			200809s 0 0 eng d
022			_a1556-1380
024	7		_a10.1097/JTO.0b013e318174e085 _2doi
040			_aNLM _beng _cNLM
100	1		_aBlumenschein, George
245	0	0	_aSorafenib in lung cancer: clinical developments and future directions. _h[electronic resource]
260			_bJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer _cJun 2008
300			_aS124-7 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aBenzenesulfonates _xadministration & dosage
650	0	4	_aCarcinoma, Non-Small-Cell Lung _xdrug therapy
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aForecasting
650	0	4	_aHumans
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMale
650	0	4	_aNeoplasm Staging
650	0	4	_aNeovascularization, Pathologic _xprevention & control
650	0	4	_aNiacinamide _xanalogs & derivatives
650	0	4	_aPhenylurea Compounds
650	0	4	_aPyridines _xadministration & dosage
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aReceptors, Vascular Endothelial Growth Factor _xantagonists & inhibitors
650	0	4	_aRisk Assessment
650	0	4	_aSorafenib
650	0	4	_aSurvival Analysis
650	0	4	_aTreatment Outcome
650	0	4	_aVascular Endothelial Growth Factors _xantagonists & inhibitors
773	0		_tJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer _gvol. 3 _gno. 6 Suppl 2 _gp. S124-7
856	4	0	_uhttps://doi.org/10.1097/JTO.0b013e318174e085 _zAvailable from publisher's website
999			_c18013095 _d18013095